James McNulty, A.B., Sc.B.

Name, Degree: James McNulty, A.B., Sc.B.
Role(s) in Task Force and Work Group: Member, Task Force
Institutional Affiliation(s): National Alliance on Mental Illness
City, State: Arlington, VA

Biographical Sketch:

Member, DSM-V Task Force
President Emeritus, National Alliance for the Mentally Ill
Pascoag, RI

Mr. McNulty is president emeritus of the National Alliance for the Mentally Ill (NAMI) National Board of Directors. He currently serves as the director of NAMI’s STAR Center, a National Technical Assistance Center founded by SAMHSA’s Center for Mental Health Services. Previously, he served as director of Consumer and Recovery Services for Public Sector Solutions at Magellan Health Services, the nation’s leading national managed behavioral health organization. Mr. McNulty currently also serves as president of the Manic Depressive and Depressive Association of Rhode Island, a position he was first elected to in 1989. He is also presently serving as vice chair of the NAMI National Consumer Council Executive Committee. He has recently stepped down from the boards of directors of the National Association of State Mental Health Planning and Advisory Councils and the National Association of Consumer/Survivor Mental Health Administrators.

He is a graduate of Brown University in Providence, with a degree in International Relations. He spent much of his early life in Latin America and Europe, becoming fluent in several languages.

Mr. McNulty has been living with bipolar disorder his entire adult life. Not diagnosed until his mid-thirties, when the illness began to manifest itself in a particularly devastating way, Mr. McNulty has experienced the full impact of mental illness, at first hand and as a family member of other individuals with mental illness. His first experience of mental illness (then diagnosed as a “nervous breakdown”) occurred as a college sophomore in 1970; at that time the main treatment model was psychodynamic, which proved to be more effective in disrupting family relationships than treating his manic depression.

Together with other like-minded individuals who were learning to live with mental illness as well as their family members, Mr. McNulty has been facilitating peer education and support groups focused on recovery for the past 15 years. In issues pertaining to access and quality of psychiatric treatment he works to forge alliances between patient and family advocacy groups and mental health professionals and has spoken to national groups about the need for closer relationships between these groups.

Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V :   Three calendar years before  nomination and Each year thereafter through the present calendar year.  (For 2008, activities to date and commitments for remainder of year.)

Non-Profit and Advocacy Organizations

Year(s)

Role

Association for the Accreditation of Human Research Protection Programs, Washington, DC

2007-

Board Member

NAMI

2004

Vice Chair, Consumer Council


The two tables below represent Mr. James McNulty’s disclosure of significant interests and affiliations for:  (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.

Mr. James McNulty has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.

KEY NUMBER:
1. Consultation Fees  (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)5. Stock or other financial options 

6. Expert testimony
7.  Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10.  Other  (specify)

Disclosure of significant interests including:  Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force

Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on  the DSM-V Task Force, to the present.  (For 2008, activities to date and commitments for remainder of year.)

 

Commercial or Other Organization

 

Year(s)

 

Key #(s)

 

Magellan Healthcare

 

2006-2007

 

2

 

NAMI

 

2007-

 

2

AstraZeneca

2003

4

SmithKlineBeecham

2003

4

Innovative Medical Education

2003

4


 

From: 
Email:  
To: 
Email:  
Subject: 
Message: